FDA Investigation Raises Broader Questions About 510(k) Statute
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent reexamination of a contentious 510(k)-clearance revealed not only serious deviations from agency protocol in that instance, but also systemic problems with the 510(k) process itself, FDA said last week